New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
08:30 EDTCVSCVS Caremark sees Q1 net revenue growth 4.25%-5.5%, consensus $32.06B
Sees Q1 retail pharmacy net revenue growth 3%-4.5%, SSS up 1.75%-3.25%. Sees pharmacy services net revenue growth 5.5%-6.75%. Sees FY14 net retail revenue growth 0.75%-2%, PBM net revenue growth 7.25%-8.5%. Says exiting tobacco category does not affect 2014 segment operating profit guidance, EPS guidance or five-year financial targets provided at 2013 Analyst Day. Says had "overwhelmingly positive response across an array of key constituents." Regarding the impact of the Affordable Care Act, CVS says that although it remains to be seen how many people ultimately gain coverage this year, but says recent progress is "encouraging". Sees modest net positive benefit from health reform this year. Says expects to return over $5B to shareholders in 2014; says on track to achieve targeted payout ratio of 25% during 2014, more than a year ahead of schedule. Comments from slides that will be presented on the Q4 earnings conference call.
News For CVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 14, 2014
14:53 EDTCVSCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use